Correction: Predictors and responses to varying durations of BTK inhibitor bridging therapy before anti-CD19 CAR-T cell therapy in patients with relapsed/refractory DLBCL

Frontiers in Immunology 2026 Open access

Read full text
Authors: Jia Wang, Rui Cui, Yao Qi, Juan Mu, Xin Li, Qing Li, Qi Deng
DOI: 10.3389/fimmu.2026.1814535
Cited by: 0

Abstract

Correction on: Wang J, Cui R, Qi Y, Mu J, Li X, Li Q and Deng Q (2026) Predictors and responses to varying durations of BTK inhibitor bridging therapy before anti-CD19 CAR-T cell therapy in patients with relapsed/refractory DLBCL. Front. Immunol. 17:1674235. doi: 10.3389/fimmu.2026.1674235.Adding/removing text In the abstract, two typographical errors were identified. In the last sentence of the Patients and Methods section, the original version incorrectly stated: "These 33 patients were stratified into two groups based on the duration of BTKi exposure: ≥x months versus

Fields of Study & Subjects

CAR-T cell therapy research Lymphoma Diagnosis and Treatment Chronic Lymphocytic Leukemia Research

Publication details

Journal / source
Frontiers in Immunology
Volume
17
Pages
1814535–1814535
Publication date
9 March 2026
Language
EN